MX2021004185A - Polipeptidos analogos de la amilina humana y sus metodos de uso. - Google Patents

Polipeptidos analogos de la amilina humana y sus metodos de uso.

Info

Publication number
MX2021004185A
MX2021004185A MX2021004185A MX2021004185A MX2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A
Authority
MX
Mexico
Prior art keywords
methods
analog polypeptides
amylin
amylin analog
polypeptides
Prior art date
Application number
MX2021004185A
Other languages
English (en)
Inventor
Ved P Srivastava
William Blackwell
James M Way
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of MX2021004185A publication Critical patent/MX2021004185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polipéptidos aislados que son análogos de la amilina humana; los polipéptidos análogos de amilina divulgados tienen propiedades fisicoquímicas beneficiosas relacionadas con la amilina endógena, tales como una vida media (ti/2) de eliminación más prolongada y una solubilidad y estabilidad térmica mejoradas; esta invención también se relaciona con métodos para usar los polipéptidos análogos de amilina divulgados en una variedad de indicaciones terapéuticas, así como métodos para producir los mismos; los polipéptidos análogos de amilina divulgados son de particular utilidad en los métodos de tratamiento de enfermedades o trastornos metabólicos, tal como las diabetes de los tipos 1 y 2 y también proveen pérdida de peso.
MX2021004185A 2018-10-11 2019-10-10 Polipeptidos analogos de la amilina humana y sus metodos de uso. MX2021004185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11
PCT/US2019/055696 WO2020077129A1 (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Publications (1)

Publication Number Publication Date
MX2021004185A true MX2021004185A (es) 2021-09-08

Family

ID=68393080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004185A MX2021004185A (es) 2018-10-11 2019-10-10 Polipeptidos analogos de la amilina humana y sus metodos de uso.

Country Status (14)

Country Link
US (1) US12018059B2 (es)
EP (1) EP3864031A1 (es)
JP (1) JP2022504596A (es)
KR (1) KR20210091705A (es)
CN (1) CN113195524A (es)
AR (1) AR116632A1 (es)
AU (1) AU2019357621A1 (es)
BR (1) BR112021006823A2 (es)
CA (1) CA3116023A1 (es)
IL (1) IL282079A (es)
MX (1) MX2021004185A (es)
SG (1) SG11202103586UA (es)
TW (1) TW202028228A (es)
WO (1) WO2020077129A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021260870A1 (en) * 2020-04-20 2022-12-08 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
DK4021929T5 (da) * 2020-09-24 2023-07-17 Gubra As hAM15-52-analoger med forbedret amylinreceptor (hAMY3R)-potens
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
HU224350B1 (hu) 1993-08-09 2005-08-29 Société de Conseils de Recherches et d'ApplicationScientifiques, S.A.S. Á Gyógyhatású peptidszármazékok
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
PT1238659E (pt) 1996-02-02 2005-01-31 Alza Corp Libertacao sustentada de um agente activo utilizando um sistema implantavel
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
PT1041975E (pt) 1997-12-22 2003-01-31 Alza Corp Membranas de controlo de taxa para dispositivos de fornecimento controlado de drogas
JP4173635B2 (ja) 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド 膜プラグ保持機構を有する浸透供給装置
ES2378675T3 (es) 1997-12-30 2012-04-16 Intarcia Therapeutics, Inc Sistema de suministro de un agente beneficioso con una membrana obturadora
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
AU771132B2 (en) 1998-12-31 2004-03-11 Intarcia Therapeutics, Inc. Osmotic delivery system having space efficient piston
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DE60023361T2 (de) 1999-12-21 2006-04-27 Alza Corp., Mountain View Ventil für osmotische vorrichtungen
AU6323001A (en) 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
KR100593348B1 (ko) 2001-08-23 2006-06-26 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
BR0312429A (pt) 2002-06-26 2005-04-19 Alza Corp Pistão de deformidade mìnima e de volume eficiente para sistemas de distribuição de drogas por osmose
US8168233B2 (en) 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
CN100548411C (zh) 2003-03-31 2009-10-14 精达制药公司 设置有内部压力释放部件的渗透泵
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
NZ548978A (en) 2004-02-11 2009-10-30 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007104789A2 (en) * 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2340261B1 (en) * 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
BRPI1006943A2 (pt) 2009-01-22 2021-06-15 Unigene Laboratories Inc. peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes
NZ595021A (en) 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
BR112012026174A2 (pt) 2010-04-15 2019-09-24 Genentech Inc anticorpo isolado, ácido nucleico isolado, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, doença ou disfunção, uso do anticorpo, método de tratamento, de determinação e de separação
US20140221282A1 (en) * 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
US8722849B2 (en) 2011-06-10 2014-05-13 Novo Nordisk A/S Polypeptides
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
EP3129041B1 (en) 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
AR101742A1 (es) 2014-09-04 2017-01-11 Novo Nordisk As Agonista del receptor de calcitonina y amilina
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues

Also Published As

Publication number Publication date
CN113195524A (zh) 2021-07-30
CA3116023A1 (en) 2020-04-16
WO2020077129A1 (en) 2020-04-16
EP3864031A1 (en) 2021-08-18
BR112021006823A2 (pt) 2021-07-27
AR116632A1 (es) 2021-05-26
US12018059B2 (en) 2024-06-25
SG11202103586UA (en) 2021-05-28
TW202028228A (zh) 2020-08-01
IL282079A (en) 2021-05-31
US20200115430A1 (en) 2020-04-16
AU2019357621A1 (en) 2021-05-27
JP2022504596A (ja) 2022-01-13
KR20210091705A (ko) 2021-07-22

Similar Documents

Publication Publication Date Title
MX2021004185A (es) Polipeptidos analogos de la amilina humana y sus metodos de uso.
MX2023010869A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
MX2022005399A (es) Compuestos.
PH12020551742A1 (en) Gip derivatives and uses thereof
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
MY193457A (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
MX2018005387A (es) Variantes de fgf21.
MY197024A (en) Amylin analogues
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
PH12019550241A1 (en) Mic-1 compounds and uses thereof
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018008644A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espir o-[4.5]-decano.
ZA202201828B (en) Therapeutic fusion proteins
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
PH12020551659A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
CR20220278A (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
PH12019502850A1 (en) AMIDE DERIVATIVES AS Nav1.7 AND Nav1.8 BLOCKERS
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
MX2020001434A (es) Analogos de insulina acilados novedosos y usos de estos.
MX2023007224A (es) Agonistas del receptor del polipeptido tipo glucagon 1 (glp-1) de accion prolongada y metodos de uso de los mismos.
BR112022020956A2 (pt) Análogos de peptídeo tirosina tirosina (pyy) de ação prolongada e métodos de uso
ZA202200331B (en) Naltrexone formulation